Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurogenetics
Erschienen in: neurogenetics 2/2019

25.03.2019 | Review Article

Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era

verfasst von: Stefania Zampatti, Luca Colantoni, Claudia Strafella, Rosaria Maria Galota, Valerio Caputo, Giulia Campoli, Giulia Pagliaroli, Stefania Carboni, Julia Mela, Cristina Peconi, Stefano Gambardella, Raffaella Cascella, Emiliano Giardina

Erschienen in: Neurogenetics | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic neuromuscular disorder which mainly affects the muscles of the face, shoulder, and upper arms. FSHD is generally associated with the contraction of D4Z4 macrosatellite repeats on 4q35 chromosome or mutations in SMCHD1, which are responsible of the toxic expression of DUX4 in muscle tissue. Despite the recent application of NGS techniques in the clinical practice, the molecular diagnosis of FSHD is still performed with dated techniques such as Southern blotting. The diagnosis of FSHD requires therefore specific skills on both modern and less modern analytical protocols. Considering that clinical and molecular diagnosis of FSHD is challenging, it is not surprising that only few laboratories offer a comprehensive characterization of FSHD, which requires the education of professionals on traditional techniques even in the era of NGS. In conclusion, the study of FSHD provides an excellent example of using classical and modern molecular technologies which are equally necessary for the analysis of DNA repetitive traits associated with specific disorders.
Literatur
1.
Himeda CL, Jones TI, Jones PL (2015) Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. Antioxid Redox Signal 22(16):1463–1482CrossRefPubMedPubMedCentral
2.
Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E, Weinreich SS, Verbeek AL, van Engelen BG (2014) Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 83(12):1056–1059CrossRefPubMedPubMedCentral
3.
4.
DeSimone AM, Pakula A, Lek A, Emerson CP Jr (2017) Facioscapulohumeral muscular dystrophy. Compr Physiol 7(4):1229–1279CrossRefPubMed
5.
Nguyen K, Puppo F, Roche S, Gaillard MC, Chaix C, Lagarde A, Pierret M, Vovan C, Olschwang S, Salort-Campana E, Attarian S, Bartoli M, Bernard R, Magdinier F, Levy N (2017) Molecular combing reveals complex 4q35 rearrangements in facioscapulohumeral dystrophy. Hum Mutat 38(10):1432–1441CrossRefPubMed
6.
Salani M, Morini E, Scionti I, Tupler R (2012) Facioscapulohumeral muscular dystrophy: from clinical data to molecular genetics and return. In: Ashraf Zaher (ed) Neuromuscular disorders. IntechOpen, pp.21–54
7.
Statland JM, Tawil R (2016) Facioscapulohumeral muscular dystrophy. Continuum (Minneap Minn) 22(6):1916–1931
8.
Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van Engelen BG (2016) What’s in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol 16(3):201–207CrossRefPubMed
9.
Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M (2015) Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 85(4):357–364CrossRefPubMedPubMedCentral
10.
Goselink RJM, Mul K, van Kernebeek CR, Lemmers RJLF, van der Maarel SM, Schreuder THA, Erasmus CE, Padberg GW, Statland JM, Voermans NC, van Engelen BGM (2019) Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy. Neurology. 92(4):378–385CrossRef
11.
Gaillard MC, Roche S, Dion C, Tasmadjian A, Bouget G, Salort-Campana E, Vovan C, Chaix C, Broucqsault N, Morere J, Puppo F, Bartoli M, Levy N, Bernard R, Attarian S, Nguyen K, Magdinier F (2014) Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers. Neurology 83(8):733–742CrossRefPubMed
12.
Larsen M, Rost S, El Hajj N, Ferbert A, Deschauer M, Walter MC, Schoser B, Tacik P, Kress W, Müller CR (2015) Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1. Eur J Hum Genet 23(6):808–816CrossRefPubMed
13.
Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camaño P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, Tawil R, Frants RR, van der Maarel SM (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329(5999):1650–1653CrossRefPubMedPubMedCentral
14.
Cascella R, Strafella C, Caputo V, Galota RM, Errichiello V, Scutifero M, Petillo R, Marella GL, Arcangeli M, Colantoni L, Zampatti S, Ricci E, Deidda G, Politano L, Giardina E (2018) Digenic inheritance of shortened repeat units of the D4Z4 region and a loss-of-function variant in SMCHD1 in a family with FSHD. Front Neurol 9. https://​doi.​org/​10.​3389/​fneur.​2018.​01027
15.
Lemmers RJ, van der Vliet PJ, van der Gaag KJ, Zuniga S, Frants RR, de Knijff P, van der Maarel SM (2010) Worldwide population analysis of the 4q and 10q subtelomeres identifies only four discrete interchromosomal sequence transfers in human evolution. Am J Hum Genet 86:364–377CrossRefPubMedPubMedCentral
16.
17.
Gatica LV, Rosa AL (2016) A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 26(12):844–852CrossRefPubMed
18.
Jansz N, Chen K, Murphy JM, Blewitt ME (2017) The epigenetic regulator SMCHD1 in development and disease. Trends Genet 33(4):233–243CrossRefPubMed
19.
Dion C, Roche S, Laberthonnière C, Broucqsault N, Mariot V, Xue S, Gurzau AD, Nowak A, Gordon CT, Gaillard MC, El-Yazidi C, Thomas M, Schlupp-Robaglia A, Missirian C, Malan V, Ratbi L, Sefiani A, Wollnik B, Binetruy B1, Salort Campana E, Attarian S, Bernard R, Nguyen K, Amiel J, Dumonceaux J, Murphy JM, Déjardin J, Blewitt ME, Reversade B, Robin JD, Magdinier F (2019) SMCHD1 is involved in de novo methylation of the DUX4-encoding D4Z4 macrosatellite. Nucleic Acids Res gkz005. doi:https://​doi.​org/​10.​1093/​nar/​gkz005
20.
Liu L, Leng L, Liu C, Lu C, Yuan Y, Wu L, Gong F, Zhang S, Wei X, Wang M, Zhao L, Hu L, Wang J, Yang H, Zhu S, Chen F, Lu G, Shang Z, Lin G (2019) An integrated chromatin accessibility and transcriptome landscape of human pre-implantation embryos. Nat Commun 10(1):364CrossRefPubMedPubMedCentral
21.
Hendrickson PG, Doráis J, Grow E, Whiddon JL, Lim JW, Wike CL, Weaver BD, Pflueger C, Emery BR, Wilcox AL, Nix DA, Peterson CM, Tapscott SJ, Carrell DT, Cairns BR (2017) Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons. Nat Genet 49(6):925–934CrossRefPubMedPubMedCentral
22.
De Iaco A, Planet E, Coluccio A, Verp S, Duc J, Trono D (2017) DUX-family transcription factors regulate zygotic genome activation in placental mammals. Nat Genet 49(6):941–945CrossRefPubMedPubMedCentral
23.
Whiddon JL, Langford AT, Wong CJ, Zhong JW, Tapscott SJ (2017) Conservation and innovation in the DUX4-family gene network. Nat Genet 49(6):935–940CrossRefPubMedPubMedCentral
24.
de Greef JC, Lemmers RJ, Camaño P, Day JW, Sacconi S, Dunand M, van Engelen BG, Kiuru-Enari S, Padberg GW, Rosa AL, Desnuelle C, Spuler S, Tarnopolsky M, Venance SL, Frants RR, van der Maarel SM, Tawil R (2010) Clinical features of facioscapulohumeral muscular dystrophy. Neurology 75(17):1548–1554CrossRefPubMedPubMedCentral
25.
Lemmers RJ, Goeman JJ, van der Vliet PJ, van Nieuwenhuizen MP, Balog J, Vos-Versteeg M, Camano P, Ramos Arroyo MA, Jerico I, Rogers MT, Miller DG, Upadhyaya M, Verschuuren JJ, Lopez de MunainArregui A, van Engelen BG, Padberg GW, Sacconi S, Tawil R, Tapscott SJ, Bakker B, van der Maarel SM (2015) Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Hum Mol Genet 24:659–669CrossRefPubMed
26.
Balog J, Thijssen PE, de Greef JC, Shah B, van Engelen BG, Yokomori K, Tapscott SJ, Tawil R, van der Maarel SM (2012) Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD. Epigenetics 7:579–584CrossRefPubMedPubMedCentral
27.
Rosenberg RN, Pascual JM (2014) Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. Section 11, Chapter 97:1169–1176. eBook ISBN:9780124105492
28.
Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, Amell AM, van der Vliet PJ, Almomani R, Straasheijm KR, Krom YD, Klooster R, Sun Y, den Dunnen JT, Helmer Q, Donlin-Smith CM, Padberg GW, van Engelen BG, de Greef JC, Aartsma-Rus AM, Frants RR, de Visser M, Desnuelle C, Sacconi S, Filippova GN, Bakker B, Bamshad MJ, Tapscott SJ, Miller DG, van der Maarel SM (2012) Digenic inheritance of an SMCHD1 mutation and an FSHD- permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 44:1370–1374CrossRefPubMedPubMedCentral
29.
Sacconi S, Lemmers RJ, Balog J, van der Vliet PJ, Lahaut P, van Nieuwenhuizen MP, Straasheijm KR, Debipersad RD, Vos-Versteeg M, Salviati L, Casarin A, Pegoraro E, Tawil R, Bakker E, Tapscott SJ, Desnuelle C, van der Maarel SM (2013) The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet 93(4):744–751CrossRefPubMedPubMedCentral
30.
van den Boogaard ML, Lemmers RJLF, Balog J, Wohlgemuth M, Auranen M, Mitsuhashi S, van der Vliet PJ, Straasheijm KR, van den Akker RFP, Kriek M, Laurense-Bik MEY, Raz V, van Ostaijen-Ten Dam MM, Hansson KBM, van der Kooi EL, Kiuru-Enari S, Udd B, van Tol MJD, Nishino I, Tawil R, Tapscott SJ, van Engelen BGM, van der Maarel SM (2016) Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy. Am J Hum Genet 98(5):1020–1029CrossRefPubMedPubMedCentral
31.
Sakellariou P, Kekou K, Fryssira H, Sofocleous C, Manta P, Panousopoulou A, Gounaris K, Kanavakis E (2012) Mutation spectrum and phenotypic manifestation in FSHD Greek patients. Neuromuscul Disord 22(4):339–349CrossRefPubMed
32.
Ricci G, Scionti I, Sera F, Govi M, D’Amico R, Frambolli I, Mele F, Filosto M, Vercelli L, Ruggiero L, Berardinelli A, Angelini C, Antonini G, Bucci E, Cao M, Daolio J, Di Muzio A, Di Leo R, Galluzzi G, Iannaccone E, Maggi L, Maruotti V, Moggio M, Mongini T, Morandi L, Nikolic A, Pastorello E, Ricci E, Rodolico C, Santoro L, Servida M, Siciliano G, Tomelleri G, Tupler R (2013) Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain 136(Pt 11:3408–3417CrossRefPubMedPubMedCentral
33.
Salort-Campana E, Nguyen K, Bernard R, Jouve E, Solé G, Nadaj-Pakleza A, Niederhauser J, Charles E, Ollagnon E, Bouhour F, Sacconi S, Echaniz-Laguna A, Desnuelle C, Tranchant C, Vial C, Magdinier F, Bartoli M, Arne-Bes MC, Ferrer X, Kuntzer T, Levy N, Pouget J, Attarian S (2015) Low penetrance in facioscapulohumeral muscular dystrophy type 1 with large pathological D4Z4 alleles: a cross-sectional multicenter study. Orphanet J Rare Dis 10:2. https://​doi.​org/​10.​1186/​s13023-014-0218-1 CrossRefPubMedPubMedCentral
34.
Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK, Nishino I, Lin CW, Shih HH, Huang CC, Liang WC, Wang WF, Jong YJ (2013) Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord 23(4):298–305CrossRefPubMed
35.
Cascella R, Strafella C, Longo G, Manzo L, Ragazzo M, De Felici C, Gambardella S, Marsella LT, Novelli G, Borgiani P, Sangiuolo F, Cusumano A, Ricci F, Giardina E (2017) Assessing individual risk for AMD with genetic counseling, family history, and genetic testing. Eye (Lond) 32(2):446–450CrossRef
36.
Cascella R, Strafella C, Germani C, Novelli G, Ricci F, Zampatti S, Giardina E (2015) The genetics and the genomics of primary congenital glaucoma. Biomed Res Int 2015:321291CrossRefPubMedPubMedCentral
37.
Forrest LE, Delatycki MB, Skene L, Aitken M (2007) Communicating genetic information in families-a review of guidelines and position papers. Eur J Hum Genet 15(6):612–618CrossRefPubMed
38.
Sachs A, Blanchard L, Buchanan A, Norwitz E, Bianchi DW (2015) Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. Prenat Diagn 35(10):968–971CrossRefPubMed
39.
Lemmers RJ, O’Shea S, Padberg GW, Lunt PW, van der Maarel SM (2012) Best practice guidelines on genetic diagnostics of Facioscapulohumeral muscular dystrophy: workshop 9th June 2010, LUMC, Leiden, The Netherlands. Neuromuscul Disord 22(5):463–470CrossRefPubMed
40.
Tsumagari K, Chen D, Hackman JR, Bossler AD, Ehrlich M (2010) FSH dystrophy and a subtelomeric 4q haplotype: a new assay and associations with disease. J Med Genet 47(11):745–751CrossRefPubMedPubMedCentral
41.
Barat-Houari M, Nguyen K, Bernard R, Fernandez C, Vovan C, Bareil C, Khau Van Kien P, Thorel D, Tuffery-Giraud S, Vasseur F, Attarian S, Pouget J, Girardet A, Lévy N, Claustres M (2010) New multiplex PCR-based protocol allowing indirect diagnosis of FSHD on single cells: can PGD be offered despite high risk of recombination? Eur J Hum Genet 18(5):533–538CrossRefPubMed
42.
Dai Y, Li P, Wang Z, Liang F, Yang F, Fang L, Huang Y, Huang S, Zhou J, Wang D, Cui L, Wang K (2019) Single-molecule optical mapping enables accurate molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD). BioRxiv. https://​doi.​org/​10.​1101/​286104
43.
Zhang Q, Xu X, Ding L, Li H, Xu C, Gong Y, Liu Y, Mu T, Leigh D, Cram DS, Tang S (2019) Clinical application of single-molecule optical mapping to a multigeneration FSHD1 pedigree. Mol Genet Genomic Med 21:e565CrossRef
44.
Borry P, Stultiens L, Nys H, Cassiman JJ, Dierickx K (2006) Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet 70(5):374–381CrossRefPubMed
45.
46.
47.
Calandra P, Cascino I, Lemmers RJ, Galluzzi G, Teveroni E, Monforte M, Tasca G, Ricci E, Moretti F, van der Maarel SM, Deidda G (2016) Allele-specific DNA hypomethylation characterises FSHD1 and FSHD2. J Med Genet 53:348–355CrossRefPubMed
48.
Cascella R, Stocchi L, Strafella C, Mezzaroma I, Mannazzu M, Vullo V, Montella F, Parruti G, Borgiani P, Sangiuolo F, Novelli G, Pirazzoli A, Zampatti S, Giardina E (2015) Comparative analysis between saliva and buccal swabs as source of DNA: lesson from HLA-B*57:01 testing. Pharmacogenomics 16(10):1039–1046CrossRefPubMed
49.
Giardina E, Peconi C, Cascella R, Sinibaldi C, Foti Cuzzola V, Nardone AM, Bramanti P, Novelli G (2009) A multiplex molecular assay for the detection of uniparental disomy for human chromosome 7. Electrophoresis 30(11):2008–2011CrossRefPubMed
50.
Adams DR, Eng CM (2018) Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med 379(14):1353–1362CrossRefPubMed
Metadaten
Titel
Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era
verfasst von
Stefania Zampatti
Luca Colantoni
Claudia Strafella
Rosaria Maria Galota
Valerio Caputo
Giulia Campoli
Giulia Pagliaroli
Stefania Carboni
Julia Mela
Cristina Peconi
Stefano Gambardella
Raffaella Cascella
Emiliano Giardina
Publikationsdatum
25.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Neurogenetics / Ausgabe 2/2019
Print ISSN: 1364-6745
Elektronische ISSN: 1364-6753
DOI
https://doi.org/10.1007/s10048-019-00575-4

Weitere Artikel der Ausgabe 2/2019

neurogenetics 2/2019 Zur Ausgabe

Short Communication

Primary familial brain calcification caused by a novel homozygous MYORG mutation in a consanguineous Italian family

Short Communication

Pathogenic variants in AIMP1 cause pontocerebellar hypoplasia

Original Article

Association of ATXN2 intermediate-length CAG repeats with amyotrophic lateral sclerosis correlates with the distributions of normal CAG repeat alleles among individual ethnic populations

Short Communication

Truncating biallelic variant in DNAJA1, encoding the co-chaperone Hsp40, is associated with intellectual disability and seizures

Original Article

Rs10230207 genotype confers changes in HDAC9 and TWIST1, but not FERD3L in lymphoblasts from patients with intracranial aneurysm

Original Article

Overlap of polymicrogyria, hydrocephalus, and Joubert syndrome in a family with novel truncating mutations in ADGRG1/GPR56 and KIAA0556

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise